[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-diseases":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,40,72,101,123,146,175,201,233,266,292,312,334,355,384,406,426,452,474,520,545,572],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100382434","calgary-registry-for-advanced-and-therapeutic-endoscopy-100382434",false,"NCT04259580","Calgary Registry for Advanced and Therapeutic Endoscopy","CReATE","Inclusion Criteria:\n\n* any standard indication for ERCP, in the absence of standard contraindications;\n* age 18 years or over;\n* ability and willingness to give informed consent to be included in the registry and\u002For to involvement in one (or more) prospective sub-studies, or accompaniment by a surrogate who is willing and able to provide consent.\n\nExclusion Criteria:\n\n-none other than inverses of above.","ALL","18 Years",{"count":19,"type":20},6000,"ESTIMATED","30 Days","OBSERVATIONAL","The aim of the Calgary Registry for Advanced and Therapeutic Endoscopy (CReATE) is to be a high-fidelity prospective multi-centre registry. The study population consists of consecutive adult ERCP patients from September 2018 to August 2022. Informed consent is acquired for each patient. All relevant pre-procedural, procedural, peri-procedural and post-procedural data are captured in real time by a full-time third-party research assistant directly observing procedures. Outcomes are ascertained by comprehensive medical record review and patient phone interview 30 days after the index procedure. This registry also serves as a secure data collection platform for several currently recruiting prospective studies and randomized trials.",[25,26],"Biliary Disease","Pancreatic Diseases","RECRUITING","2026-04-28",{"date":30,"type":31},"2026-04-29","ACTUAL",{"date":33,"type":31},"2018-09-01",{"date":35,"type":20},"2030-12-31",{"name":37,"class":38},"University of Calgary","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100635937","phase-2-a-study-to-evaluate-safety-and-explore-efficacy-of-new-lipase-nhs7108-in-adult-participants-with-exocrine-pancreatic-insufficiency-100635937","NCT07559175","A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.","A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants With Exocrine Pancreatic Insufficiency- EPIC","EPIC","Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply:\n\n1. Participant is a male or female between 18 to 85 years of age, inclusive, at the time of signing the informed consent.\n2. Participants with clinically confirmed\\* chronic established (not due to a transient clinical diagnosis, i.e., acute pancreatitis) EPI and with a clinical indication for PERT.\n3. CFA off PERT of \\\u003C80% at screening\n4. Normal body mass index (BMI) by age and sex to ensure participant's EPI is adequately controlled in the opinion of the investigator (BMI of at least 17.0 and no greater than 35.0 kg\u002Fm²)\n5. Standard-of-care medications are allowed (antibiotics, mucolytic agents, aerosols, antacids), if on stable doses for at least 1 month prior to baseline CFA and CNA assessments and must not be altered in dose or stopped during the study.\n6. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are allowed if on stable doses for at least 3 months prior to randomization. Participants should not start taking CFTR modulators during the duration of the study.\n7. Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\n   Male Participants:\n   * Non-sterilized male participants are eligible to participate if they agree to one of the following starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up: Must agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), OR male participants with a female partner of childbearing potential must agree to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method). Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile penetration. These requirements also apply to participants in a same sex relationship.\n   * Male participants must agree not to donate sperm starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.\n\n   Female Participants:\n   * Female participants of childbearing potential (as defined in Appendix 4) are eligible to participate if they meet the following criteria: Agree not to become pregnant during the clinical study period and until the end-of-study safety follow-up. Have a negative serum pregnancy test at screening and a negative urine pregnancy test at Day 1. If heterosexually active, must agree to consistently use a form of highly effective birth control, in combination with a barrier method starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up, OR agree to stay abstinent (where abstinence is the preferred and usual lifestyle of the participant), starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up. These requirements do not apply to participants in a same sex relationship.\n   * Female participants of nonchildbearing potential are eligible to participate if one of the following conditions apply: Must have a confirmed clinical history of sterility (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy, as confirmed by review of the participant's medical records, medical examination, or medical history interview). Must be postmenopausal as defined as: amenorrhea for at least 1 year prior to screening and a laboratory confirmed serum follicle-stimulating hormone (FSH) level ≥ 40 mIU\u002FmL. Female participants on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use 1 of the non-estrogen hormonal highly effective contraception methods from screening until at and continuing throughout the clinical study period, and until the end-of-study safety follow-up if they wish to continue their HRT during the study.\n   * Female participants must agree not to donate ova starting at screening and continuing throughout the clinical study period, and until the end-of-study safety follow-up.\n   * For WOCBP only, serum pregnancy test will be performed at screening and urine pregnancy tests will be performed at the timepoints outlined in the SoA.\n   * The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n8. Participants are capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n9. Participants agree not to participate in another interventional study while participating in the study.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. Female participants who are breastfeeding at the time of screening.\n2. Previous GI surgery, except for non-invasive neonatal or early childhood procedures such as correction of hypertrophic pyloric stenosis, surgical correction of Meckel's diverticulum, volvulus, or intestinal intussusception. Hernia repair, appendectomy, cesarean section, tubal ligation, hysterectomy, polypectomy, hemorrhoidectomy, or cholecystectomy are allowed if performed at least 2 years before randomization and have no impact on intestinal transit or absorption.\n3. Participants on enteral feeding.\n4. Participants with celiac disease.\n5. Known allergy or adverse reaction history to any component of NHS7108, Zenpep®, omega-3 oil, and\u002For to any other product administered during the study, including the blue dye.\n6. Concurrent clinically significant, at the discretion of the Investigator, hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, and seasonal allergies and childhood asthma) or any other disorder that in the opinion of the Investigator may put the participant at greater safety risk, influence response to study intervention, or interfere with study assessments.\n7. Concurrent conditions having a clinically significant impact on GI motility function, with the exception of pancreatic insufficiency due to pancreatectomy or CP.\n8. Any significant clinical\u002Flaboratory\u002Fradiological sign of unstable or unexpectedly deteriorating respiratory disease during the study duration, at the discretion of the Investigator.\n9. Omega-3 supplements are prohibited during all the study periods and should be stopped at least 7 days prior to the baseline off-treatment fat absorption assessments.\n10. Participants starting new medications or changing dose within 1 month before baseline off-treatment screening assessments.\n11. Acute use of oral or intravenous antibiotics within 2 weeks prior to the first dose of study intervention.\n12. Treatment with any investigational drug or device\u002Ftreatment within the 30 days or 5 half-lives of the drug (whichever is longer) prior to first dose of study intervention.\n13. Participant has any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis at screening as judged by the Investigator OR as detailed below:\n\n    * Estimated glomerular filtration rate \\\u003C 60 mL\u002Fmin at screening visit.\n    * Total bilirubin \\> 1.5 × upper limit of normal (ULN) at screening visit.\n    * Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2 × ULN at screening visit.\n14. Positive human immunodeficiency virus (HIV) antibody test.\n15. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.\n16. Positive hepatitis C virus (HCV) antibody test result at screening or within 3 months prior to first dose of study intervention AND positive on reflex to hepatitis C RNA test.\n17. Concurrent drug or alcohol addiction that in the opinion of the Investigator would preclude participation and compliance with the study procedures.","85 Years",{"count":50,"type":20},66,"INTERVENTIONAL",[53],"PHASE2","The purpose of this study is to measure the safety and explore the efficacy of 4 different doses of the new lipase NHS7108 in participants with EPI. In this study, all participants will take NHS7108 daily for 14 days and a matching dose of standard-of-care, pancrelipase (Zenpep®) for 14 days according to Treatment Sequence assignment. Both NHS7108 and Zenpep® are oral capsules that will be taken with each of the daily 3 meals and 2 snacks. Participants will interrupt all of their usual pancrelipase\u002Fpancreatin treatment for up to 8 days during screening and for the entire 2 treatment periods, where participants will take either the new lipase NHS7108 or a matching dose of the standard-of-care pancrelipase (Zenpep®). Participants will be asked to stay in a setting that allows controlled diet and 72-hour stool collection for approximately 7 days during the screening period and again for approximately 7 days at the end of each treatment period. During these 3 supervised periods, participants will receive a standardized diet with a predefined amount of fat and protein, stools will be collected in special containers and during the last day of the treatment period, blood samples will be obtained to measure fat absorption. These are essential to ensure valid assessment of participants' fat and protein absorption. Outside the 3 supervised periods, participants will be provided with guidelines and recommendations to create their own home-controlled meals and snacks according to their preferences for the remainder of the study duration.\n\nNumber of Participants:\n\nThe aim is to have 56 participants completing the study. Assuming approximately 14% drop-out rate, approximately 66 participants will be randomized to study intervention.\n\nStudy Arms and Duration:\n\nThe total study duration for each participant will be about 100 days (approximately 14 weeks), including:\n\n* A screening period of up to approximately 28 days (might be extended up to a total of 56 days) prior to the first dose administration.\n* A crossover treatment period (2 treatment periods: approximately 14 days each, with no washout in between). For each treatment period, study intervention will be administered 5 times a day (with 3 main meals and 2 snacks). After completion of Treatment Period 1, the participant will receive and start the new treatment for Treatment Period 2.\n* An end of treatment\u002Fearly discontinuation visit within approximately 7 days of the last study intervention dose.\n* An end-of-study safety follow-up visit at 14 (±2) days after the last dose administration.\n\nVery low dose group: 10 mg NHS7108 (approximately 25,000 LU)\u002Fmain meal and snack; 25,000 LU Zenpep\u002Fmain meal and snack (50 mg NHS7108 \\[approximately 125,000 LU\\] per day; 125,000 LU Zenpep per day)\n\nLow dose group: 20 mg NHS7108 (approximately 50,000 LU)\u002Fmain meal and 10 mg NHS7108 (approximately 25,000 LU)\u002Fsnack; 50,000 LU Zenpep\u002Fmain meal and 25,000 LU Zenpep\u002Fsnack (80 mg NHS7108 \\[approximately 200,000 LU\\] per day; 200,000 LU Zenpep per day)\n\nMedium dose group: 40 mg NHS7108 (approximately 100,000 LU)\u002Fmain meal and 20 mg (approximately 50,000 LU) NHS7108\u002Fsnack; 100,000 LU Zenpep\u002Fmain meal and 50,000 LU Zenpep\u002Fsnack (160 mg \\[approximately 400,000 LU\\] NHS7108 per day; 400,000 LU Zenpep per day)\n\nHigh dose group: 60 mg NHS7108 (approximately 150,000 LU)\u002Fmain meal and 30 mg NHS7108 (approximately 75,000 LU)\u002Fsnack; 150,000 LU Zenpep\u002Fmain meal and 75,000 LU Zenpep\u002Fsnack (240 mg NHS7108 \\[approximately 600,000 LU\\] per day; 600,000 LU Zenpep per day).\n\nThe dose for participants \\\u003C 60 kg who are assigned to the high dose group will need to be weight-adjusted to ensure that they receive no more than 10,000 LU\u002Fkg\u002Fday.",[56,57,58,26],"Exocrine Pancreatic Insufficiency (EPI)","Cystic Fibrosis (CF)","Pancreatic Enzyme Abnormality",[46],"NOT_YET_RECRUITING","2026-04-23",{"date":63,"type":31},"2026-04-30",{"date":65,"type":20},"2026-04",{"date":67,"type":20},"2027-09",{"name":69,"class":70},"Aimmune Nestlé Health Science US R&D, LLC","INDUSTRY",30,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":83,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":39},"100630319","microplastics-in-pancreas-oncologic-and-metabolic-impact-100630319","NCT07486128","Microplastics in Pancreas: Oncologic and Metabolic Impact","Unveiling Microplastics in Human Pancreatic Tissue - Oncological and Metabolical Implications","PAN-Plastic","Inclusion Criteria:\n\nage between 18 and 80 years patients scheduled for elective pancreatic resection for benign or malignant pancreatic disease ability to understand and provide written informed consent no contraindications to general anesthesia\n\nExclusion Criteria:\n\nage \\\u003C18 or \\>80 years severe hepatic insufficiency (Child-Pugh class C) pregnancy or breastfeeding inability to understand the study procedures or provide informed consent","80 Years",{"count":82,"type":20},10,"12 Months","Microplastics and nanoplastics (MNPs) are emerging environmental contaminants that have been detected in several human tissues, raising concerns about their potential impact on human health. However, their presence in the human pancreas has not yet been investigated.\n\nThe aim of this prospective, single-center study is to detect and characterize microplastics in human pancreatic tissue obtained from patients undergoing pancreatic resection for benign or malignant diseases. Microplastics will also be analyzed in peripancreatic adipose tissue and peripheral blood. Advanced imaging techniques, including fluorescence microscopy, confocal microscopy, and Raman spectroscopy, will be used for identification and characterization.\n\nSecondary objectives include the evaluation of potential associations between microplastic burden and pancreatic metabolic function, assessed through clinical evaluation and metabolic testing. This proof-of-concept study aims to provide the first evidence of microplastic presence in the human pancreas and explore their potential role in metabolic dysfunction and carcinogenesis.",[26,86],"Pancreatic Neoplasms",[88,26,86,89,90,91],"Microplastics","Glucose Metabolism","Raman Spectroscopy","Pancreatic Tissue","2026-03-24",{"date":94,"type":31},"2026-03-27",{"date":96,"type":20},"2026-04-01",{"date":98,"type":20},"2027-04-01",{"name":100,"class":38},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":51,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":39},"100582261","phase-3-evaluating-the-safety-and-efficacy-of-ondansetron-in-the-prevention-of-post-endoscopic-retrograde-cholangiopancreatography-pancreatitis-100582261","NCT06861010","Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis","Inclusion Criteria:\n\n1. Age more than 18 years old.\n2. Gender: Males and Females\n3. Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.\n4. Blood amylase and lipase levels before ERCP are within the normal limits.\n\nExclusion Criteria:\n\n1. Age of less than18 years.\n2. Uncontrolled diabetes mellitus (DM)\n3. Severe bleeding tendency\n4. Impaired renal function (serum creatinine \\> 2 mg\u002FdL), (creatinine clearance \\\u003C30 ml\u002Fmin)\n5. Patients with severe heart disease.\n6. Subjects who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.\n7. Currently pregnant or nursing\n8. Admission due to established pancreatitis before ECRP\n9. Unwillingness to undergo ERCP.\n10. Previously documented allergy to ondansetron.","65 Years",{"count":109,"type":20},44,[111],"PHASE3","Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.",[26],"2026-03-12",{"date":116,"type":31},"2026-03-13",{"date":118,"type":31},"2025-03-01",{"date":120,"type":20},"2026-12-20",{"name":122,"class":38},"Tanta University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":131,"studyType":22,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":4},"100627170","research-on-construction-and-verification-of-multimodal-medical-imaging-large-model-100627170","NCT07445152","Research on Construction and Verification of Multimodal Medical Imaging Large Model","Inclusion Criteria:\n\n* Adult patients aged ≥ 18 years.\n* Patients who underwent imaging examinations (CT, MRI, ultrasound, etc.) at this hospital during the study period.\n* The examination items are consistent with the disease types or systems focused on by the study (hepatobiliary and pancreatic system).\n* Possess at least complete imaging data, radiological diagnostic reports, with relevant medical record information as supplementary modalities.\n* Patients and their legal representatives have signed an informed consent form, agreeing to the use of their de-identified data for scientific research model validation.\n\nExclusion Criteria:\n\n* Patients who refuse to sign the informed consent form.\n* Cases with unassessable images due to severe motion artifacts, incomplete scanning, or equipment abnormalities.\n* Cases with severe deficiency of clinical data or failure to match with imaging data.\n* Cases with special pathological conditions or post-operative status (e.g., extensive resection, significant structural changes after radiotherapy) that affect the consistency of model analysis.\n* Data samples with privacy protection or legal risks.",{"count":130,"type":20},2000,"4 Weeks","With the accumulation of multimodal clinical data such as medical imaging and electronic health records (EHRs), efficient utilization of multi-source information to achieve precise diagnosis and intelligent decision-making has become a core direction of medical artificial intelligence (AI). Although traditional unimodal algorithms have yielded outcomes in specific tasks, their inability to model the semantic correlations among imaging, textual, and laboratory data leads to insufficient stability and limited interpretability of diagnostic results, making it difficult to meet the needs of comprehensive decision-making in complex clinical scenarios.\n\nIn recent years, multimodal large models have demonstrated excellent cross-modal understanding and knowledge transfer capabilities in natural images and general vision-language tasks, providing a new paradigm for medical AI. However, direct application in medical scenarios still faces challenges: first, the medical semantic system differs significantly from general language models, hindering the accurate representation of disease characteristics and imaging details; second, the complex morphology of lesions and uneven sample distribution in medical data increase the difficulty of model generalization; third, clinical data involves privacy, so data security and ethical compliance serve as prerequisites for research.\n\nThe research on medical multimodal large models aims to integrate multi-source heterogeneous medical data, establish a unified semantic representation and reasoning mechanism, and realize full-process intelligent analysis including disease identification and lesion localization. This approach can not only improve the efficiency and accuracy of clinical diagnosis but also provide clinicians with interpretable and traceable auxiliary decision support, boasting broad application prospects.\n\nBased on the hospital's clinical data resources and the research team's algorithmic foundation, this study intends to construct a multimodal large model system for medical imaging diagnosis, enabling closed-loop intelligent analysis from multimodal information fusion to diagnostic report generation. The research will strictly adhere to medical ethical standards, protect patients' right to information, right to privacy, and data security. Before the official launch of the project, ethical review must be passed, and relevant regulations shall be followed to ensure the unity of scientific research and ethics, laying a compliant foundation for subsequent clinical validation and promotion.",[134,135,26,136],"Liver Diseases","Gallbladder Diseases","Artificial Intelligence (AI)","2026-02-26",{"date":139,"type":31},"2026-03-03",{"date":141,"type":20},"2026-11-15",{"date":143,"type":20},"2027-11-15",{"name":145,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":51,"phases":156,"briefSummary":158,"conditions":159,"keywords":165,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":39},"100625397","pan-clo-bu-pancreas-clostridium-butyricum-100625397","NCT07422103","PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)","Supplementation With Clostridium Butyricum CBM588 in Patients Undergoing Pancreaticoduodenectomy for Periampullary Neoplasms: A Prospective Randomized Double-Blind Study","PAN-CLO-BU","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Patients undergoing pancreaticoduodenectomy\n* Candidates for upfront surgery without previous neoadjuvant chemotherapy or radiotherapy\n* Patients with benign or malignant periampullary neoplasms\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Previous or current use of Clostridium butyricum CBM588\n* Lactose intolerance\n* Neoadjuvant chemotherapy or radiotherapy",{"count":155,"type":20},158,[157],"NA","This is a prospective, randomized, double-blind, single-center clinical trial designed to evaluate the effects of Clostridium butyricum CBM588 supplementation on postoperative diarrhea, gastrointestinal symptoms, and quality of life in patients undergoing pancreaticoduodenectomy for periampullary neoplasms. Oncological outcomes, including disease-free survival and overall survival, will be monitored as secondary endpoints during follow-up.",[160,26,161,162,163,164],"Pancreatic Cancer","Gastrointestinal Symptoms","Clostridium Butyricum Miyairi","Pancreatoduodenectomy","CBM588",[160,26,161,162],"2026-02-12",{"date":168,"type":31},"2026-02-19",{"date":170,"type":20},"2026-03-15",{"date":172,"type":20},"2030-11-30",{"name":174,"class":38},"Casa di Cura Dott. Pederzoli",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":200},"100311460","a-study-of-blood-based-biomarkers-for-pancreas-adenocarcinoma-100311460","NCT03334708","A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma","Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution\n* Patient planning to receive systemic treatment\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 2: Operable Pancreatic Cancer Cohort Inclusion Criteria\n\n* Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution\n* Patient planned to undergo upfront resection\n* No pre-operative systemic therapy nor chemoradiation therapy planned\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n* Willing to undergo a tumor biopsy\n* Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).\n\nCohort 3: Acute Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Inclusion Criteria\n\n* Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution\n* Hemoglobin \\> 8\n* ECOG performance status 0-2\n* A minimum age of 18 years old\n\nCohort 5: IPMN Control Inclusion Criteria\n\n* Confirmed diagnosis of IPMN without high risk features by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 6: Pancreatic Cyst Control Inclusion Criteria\n\n* Confirmed diagnosis of benign pancreatic cyst by the enrolling institution\n* A minimum age of 18 years old\n\nCohort 7: Healthy Control Inclusion Criteria\n\n* A minimum age of 18 years old\n\nExclusion Criteria:\n\nCohort 1: Advanced Pancreatic Cancer Cohort Exclusion Criteria\n\n* Prior chemotherapy or radiation therapy for pancreatic cancer within the last 3 months in the localized setting\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 2: Operable Pancreatic Cancer Cohort Exclusion Criteria\n\n* Neoadjuvant chemotherapy or radiation therapy is planned\n* Active second malignancy, unless low grade malignancy\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 3: Acute Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 4: Chronic Benign Pancreatic Pathology Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 5: IPMN Control Exclusion Criteria\n\n* IPMN with high risk features or planned resection\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 6: Pancreatic Cyst Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures\n\nCohort 7: Healthy Control Exclusion Criteria\n\n* Active or prior malignancy, except prior non-melanoma skin cancer\n* Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer\n* Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures",true,{"count":184,"type":20},700,"The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.",[160,26,187,188],"Pancreatitis","Pancreatic Cyst",[190],"17-257","2025-12-01",{"date":193,"type":31},"2025-12-02",{"date":195,"type":31},"2017-10-30",{"date":197,"type":20},"2026-10-30",{"name":199,"class":38},"Memorial Sloan Kettering Cancer Center",13,{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":209,"targetDuration":211,"studyType":22,"phases":4,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":39},"100384895","ucsf-panc-cyst-registry-100384895","NCT04291651","UCSF PANC Cyst Registry","Population-Based Analysis of Neoplastic Changes in Cystic Lesions of the Pancreas.","UCSF PCR","Inclusion Criteria:\n\n* The inclusion criteria for this study are intentionally broad. Eligible patients for prospective enrollment will include\n* Adults ≥ 30 years of age\n* Have a radiographic or endoscopic diagnosis of at least one pancreatic cysts regardless of treatment status,\n* No history of pancreatic cancer,\n* Can speak and read English,\n* Have access to a computer or mobile device (\\~95% of U.S. population); and\n* Are able to complete an electronic informed consent.\n\nExclusion Criteria:\n\n* Patients who don't speak English,\n* Don't have access to a computer or mobile device; or\n* Patients who have a cancer diagnosis.",{"count":210,"type":20},4000,"10 Years","Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to prevent unnecessary resection of indolent disease, with associated risks of infections, bleeding, diabetes, and costly disability. Unfortunately, there is little information on the epidemiology and natural history of pancreatic cysts to help guide management.",[188,86,160,26,214,215,216,217],"Pancreatic Intraductal Papillary Mucinous Neoplasm","Intraductal Papillary Mucinous Neoplasm","Pancreatic Ductal Adenocarcinoma","Mucinous Cyst",[188,219,160,215,220,221,222,223],"Pancreatic Cystic Lesion","Serous Cystadenoma","Mucinous Cystic Neoplasm","Cancer Epidemiology","Early Detection Research","2025-09-16",{"date":226,"type":31},"2025-09-18",{"date":228,"type":31},"2019-10-08",{"date":230,"type":20},"2030-01-01",{"name":232,"class":38},"University of California, San Francisco",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":240,"maxAge":17,"enrollmentInfo":241,"targetDuration":4,"studyType":51,"phases":243,"briefSummary":245,"conditions":246,"keywords":252,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":39},"100594803","phase-4-comparison-of-the-effectiveness-of-paracetamol-with-ibuprofen-or-paracetamol-with-metamizole-in-treating-pain-in-acute-pancreatitis-in-children-100594803","NCT07024199","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial","Inclusion Criteria:\n\n* diagnosis of AP according to the INSPPIRE mentioned above criteria,\n* age from 3 to 18 years of age,\n* abdominal pain on admission assessed on the Numerical Rating Scale (NRS) or FLACC \\>= 4 points,\n* no analgesic treatment before enrolment in the study OR the last dose of analgesic drug (paracetamol, ibuprofen, metamizole) taken ≥ 6 hours before enrolment for examination,\n* consent of legal guardians and the child (in the case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria - patients:\n\n* who took the last dose of painkiller (paracetamol, ibuprofen, metamizole) \\\u003C 6 hours before entering the study,\n* allergic to acetylsalicylic acid, other NSAIDs, paracetamol, metamizole,\n* with inflammatory bowel disease,\n* with gastrointestinal bleeding and other active bleeding,\n* with gastric and\u002For duodenal ulcer disease,\n* chronically taking paracetamol, NSAIDs, metamizole,\n* with liver failure,\n* with heart failure according to the NYHA II-IV scale,\n* with acute and chronic renal failure,\n* with cancer,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients \\> 16 years of age).","3 Years",{"count":242,"type":20},78,[244],"PHASE4","The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.",[247,248,249,26,250,187,251],"Pancreatitis, Acute","Pain, Acute","Pancreatic Disease","Gastroenterology","Paediatrics",[253,254,255,256],"acute pancreatitis","acute pain","painkillers","pancreatitis","2025-08-18",{"date":259,"type":31},"2025-08-24",{"date":261,"type":20},"2025-09",{"date":263,"type":20},"2027-06-01",{"name":265,"class":38},"Medical University of Warsaw",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":273,"targetDuration":4,"studyType":51,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":39},"100594753","the-22g-franseen-needle-combined-with-different-aspiration-techniques-for-endoscopic-ultrasound-guided-fine-needle-biopsy-100594753","NCT07023549","The 22G Franseen Needle Combined With Different Aspiration Techniques for Endoscopic Ultrasound-guided Fine-needle Biopsy","Comparing the Sample Quality of 22G Franseen Needle Combined With Different Aspiration Techniques in Endoscopic Ultrasound-Guided Fine-Needle Biopsy of Pancreatic Solid Lesions: A Randomized Controlled Multicenter Clinical Study","Inclusion Criteria:\n\n（1）18-80 years old (inclusive), male and female; （2）patients with pancreatic solid mass \\> 1cm detected by CT\u002FMRI\u002FPET-CT or EUS and requiring EUS-FNB diagnosis.\n\n（3）written informed consent was obtained.\n\nExclusion Criteria:\n\n1. contraindications to endoscopy, such as severe cardiovascular and cerebrovascular diseases;\n2. bleeding coagulation dysfunction (prothrombin international normalized ratio ≥1.5, platelet count ≤ 50 000) or use of antiplatelet drugs;\n3. confirmed pregnancy or possible pregnancy;\n4. pathological diagnosis has been obtained by other methods;\n5. refuse to participate in the study, are participating in another observational clinical trial, or have participated in another clinical trial within 60 days;\n6. other situations where EUS-FNB could not be performed.",{"count":274,"type":20},270,[157],"The goal of this clinical study is to compare the tissue adequacy, cellularity, blood contamination, accuracy, sensitivity, specificity of the 22G Franseen needle combined with three different suction techniques (dry-suction, wet-suction, and slow-pull) in Endoscopic ultrasound-guided fine-needle biopsy for solid pancreatic lesions.",[26],[279,280,281,282],"22G Franseen needle","solid pancreatic lesion","aspiration technique","Endoscopic ultrasound-guided fine-needle biopsy","2025-06-15",{"date":285,"type":31},"2025-06-17",{"date":287,"type":20},"2025-07-01",{"date":289,"type":20},"2027-05-31",{"name":291,"class":38},"Changhai Hospital",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":299,"targetDuration":4,"studyType":51,"phases":300,"briefSummary":301,"conditions":302,"keywords":303,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":39},"100594754","the-22g-trident-needle-combined-with-different-aspiration-techniques-for-endoscopic-ultrasound-guided-fine-needle-biopsy-100594754","NCT07023562","The 22G Trident Needle Combined With Different Aspiration Techniques for Endoscopic Ultrasound-guided Fine-needle Biopsy","Comparing the Sample Quality of 22G Trident Needle Combined With Different Aspiration Techniques in EUS-Guided Fine-Needle Biopsy of Pancreatic Solid Lesions: A Randomized Controlled Multicenter Clinical Study","Inclusion Criteria:\n\n* (Before the trial, subjects must meet all of the requirements listed below in order to be enrolled)\n\n  1. 18-80 years old (inclusive), male and female;\n  2. patients with pancreatic solid mass \\> 1cm detected by CT\u002FMRI\u002FPET-CT or EUS and requiring EUS-FNB diagnosis.\n  3. written informed consent was obtained.\n\nExclusion Criteria:\n\n* (Before the trial, participants could not be enrolled if they met any of the following requirements)\n\n  1. contraindications to endoscopy, such as severe cardiovascular and cerebrovascular diseases;\n  2. bleeding coagulation dysfunction (prothrombin international normalized ratio ≥1.5, platelet count ≤ 50 000) or use of antiplatelet drugs;\n  3. confirmed pregnancy or possible pregnancy;\n  4. pathological diagnosis has been obtained by other methods;\n  5. refuse to participate in the study, are participating in another observational clinical trial, or have participated in another clinical trial within 60 days.\n  6. other situations where EUS-FNB could not be performed.",{"count":274,"type":20},[157],"The goal of this clinical study is to compare the tissue adequacy, cellularity, blood contamination, accuracy, sensitivity, specificity of the 22G Trident needle combined with three different aspiration techniques (dry-suction, wet-suction, and slow-pull) in Endoscopic ultrasound-guided fine-needle biopsy for solid pancreatic lesions.",[26],[304,280,305],"EUS-FNB","sample processing",{"date":285,"type":31},{"date":308,"type":20},"2025-06-25",{"date":310,"type":20},"2027-05-26",{"name":291,"class":38},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":182,"sex":16,"minAge":318,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":333},"100595276","early-diagnosis-of-pancreatic-cancer-duodenal-fluid-based-biomarker-exploratory-study-100595276","NCT07030348","Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study","Inclusion Criteria:\n\nAmong the patients requiring gastro-duodenal endoscopy, endoscopic ultrasound, or ERCP for medical purposes, the pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.\n\n1. Be at least 19 years old.\n2. Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.\n3. A biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC).\n4. Suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.\n\nThe non-pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.\n\n1. Be at least 19 years old.\n2. Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.\n3. Patients with pancreatic cystic tumors or patients with acute or chronic pancreatitis.\n4. No evidence of a pancreatic disease.\n\nExclusion Criteria:\n\nThe exclusion criteria for the pancreatic cancer and the non-pancreatic cancer groups will be:\n\n1. Innate or post-surgical anatomy that precludes direct sampling of duodenal fluid.\n2. Hemodynamically unstable and unable to have an endoscopy performed.\n3. A large amount of ascites fluid that is not controlled and unable to have an endoscopy performed.\n4. A coagulation disorder that cannot be corrected and unable to have an endoscopy performed.","19 Years",{"count":320,"type":20},263,"Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic cancer patients are operable or borderline operable.\n\nTherefore, there is an unmet need for early diagnosis of pancreatic cancer; however, biomarkers related to this are not well understood. This study aims to identify biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic juice, which can be easily obtained through an endoscopy.",[323,26],"Pancreatic Cancers","2025-06-12",{"date":326,"type":31},"2025-06-22",{"date":328,"type":31},"2024-01-02",{"date":330,"type":20},"2026-12-31",{"name":332,"class":38},"Do Hyun Park",3,{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":341,"targetDuration":4,"studyType":51,"phases":343,"briefSummary":344,"conditions":345,"keywords":346,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":354,"locationsCount":39},"100592529","fine-needle-biopsy-combined-with-macroscopic-on-site-evaluation-for-diagnosis-of-solid-pancreatic-lesions-100592529","NCT06994611","Fine-needle Biopsy Combined With Macroscopic On-site Evaluation for Diagnosis of Solid Pancreatic Lesions","Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Macroscopic On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Prospective Multicenter Randomized Controlled Non-Inferiority Trial","Inclusion Criteria:\n\n* (Before the trial, subjects must meet all of the requirements listed below in order to be enrolled)\n\n  1. 18-80 years old (inclusive), male and female;\n  2. patients with pancreatic solid mass \\> 1cm detected by CT\u002FMRI\u002FPET-CT or EUS and requiring EUS-FNB diagnosis.\n  3. written informed consent was obtained;\n\nExclusion Criteria:\n\n* (Before the trial, participants could not be enrolled if they met any of the following requirements)\n\n  1. contraindications to endoscopy, such as severe cardiovascular and cerebrovascular diseases;\n  2. bleeding coagulation dysfunction (prothrombin international normalized ratio ≥1.5, platelet count ≤ 50 000) or use of antiplatelet drugs;\n  3. confirmed pregnancy or possible pregnancy;\n  4. pathological diagnosis has been obtained by other methods;\n  5. refuse to participate in the study, are participating in another observational clinical trial, or have participated in another clinical trial within 60 days.\n  6. other situations where EUS-FNB could not be performed.",{"count":342,"type":20},148,[157],"The goal of this clinical trial is to compare the diagnostic efficacy, core tissue acquisition ability, number of punctures and puncture time of macroscopic on-site evaluation (MOSE) and two punctures alone in Endoscopic ultrasound guided fine-needle biopsy (EUS-FNB) for solid pancreatic lesions. The main questions it aims to answer is: whether the diagnostic accuracy of EUS-FNB performed with two needle passes is not inferior to that of MOSE.\n\nParticipants with solid pancreatic lesions who needs histological diagnosis will receive EUS-FNB using 22G Franseen.\n\nIn Group 1, the macroscopically visible core (MVC) of the specimen was assessed. If the MVC of the sample obtained from the first needle was ≥10mm, the tissue strip was placed in Bottle A and fixed with formalin. A second needle was then used to obtain another tissue strip, which was directly placed into Bottle B containing formalin. However, if the MVC of the first needle sample was \\\u003C 10mm, the puncture procedure was continued until the cumulative length of sample's MVC was ≥10mm, and all the sample collected during this process were placed into Bottle A and fixed with formalin. In Group 2, two needles were used to obtain tissue strips, and all the tissue strips were placed into Bottle A formalin.\n\nResearchers will compare the diagnostic efficacy, core tissue acquisition ability, number of punctures and puncture time between the MOSE technique and two-needle puncture method.",[26],[304,280,305,347],"22D Franseen Needle","2025-06-05",{"date":350,"type":31},"2025-06-06",{"date":308,"type":20},{"date":353,"type":20},"2026-08-26",{"name":291,"class":38},{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":51,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":39},"100577457","first-in-human-integrated-endoscopic-ultrasound-eus-navigation-system-clinical-study-100577457","NCT06798545","First-in-human Integrated Endoscopic Ultrasound (EUS) Navigation System Clinical Study","EZ-EUS1","Inclusion Criteria:\n\n* Man or woman over the age of 18 years old.\n* Patient having a EUS procedure for pancreas study planned within the frame of his or her clinical care.\n* Patient whom pre-operative imaging indicates one lesion, a suspicion of lesion, chronic pancreatitis or fatty pancreas.\n* Patient with a good definition on the CT scan done within the year to the EUS.\n* Patient able to receive and understand information related to the study and give his or her written consent.\n* Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n* Patient with altered anatomy of the upper digestive tract due to previous surgery.\n* Patient with known abnormal anatomy of the upper digestive tract.\n* Patient wearing a pacemaker.\n* Patients with comorbidities that may increase the risk of perforation.\n* Patient presenting, according to the investigator's judgment, a disease which may prevent participation in the procedures provided for by the study.\n* Patient with an ASA \\>3. Patient with ASA=3 must be validated by the Principal\n* Investigator (PI).\n* Patient unable to tolerate general anesthesia.\n* Patient with a body mass index (BMI) \\\u003C 18,5 and \\> 40.\n* Patient with weight variations \\>10% between the date on which the CT scan was performed and the date of the procedure.\n* Pregnant or lactating patient.\n* Patient in exclusion period (determined by a previous or a current study).\n* Patient under guardianship or trusteeship.\n* Patient under the protection of justice of deprives of liberty.\n* Patient in situation of emergency\n\nPerprocedure exclusion criteria\n\n• Patient in need of the balloon during the navigation will be excluded of the study (Experimental group)",{"count":363,"type":20},64,[157],"The complexity of the medical expertise required for endoscopic manipulation and image interpretation complicates the implementation of echo-endoscopy (or EUS for \"Endoscopic Ultrasound\").\n\nThe \"EZ-EUS\" system is designed to help the operator understand the orientation and the position of the probe tip in the patient. This system offers navigation similar to that of the Global Positioning System (GPS), but for EUS procedures. To achieve this, it uses a 3D model based on scanner imaging data recorded before the procedure.\n\nIn this study, the intended purpose of the \"EZ-EUS\" system is to help echo-endoscopy operators to easily identify and assess the pancreatic gland, and to facilitate the detection of any lesions.\n\nThe hypothesis is that, thanks to this tool, procedure times will be shortened, and the pancreas and its lesions will be fully imaged to facilitate their localization and characterization.",[26],[368,369,370,371,372,373,374],"endoscopic ultrasound","EUS","navigation","pancreatic disease","training","education","learning curve","2025-04-29",{"date":377,"type":31},"2025-04-30",{"date":379,"type":31},"2025-01-28",{"date":381,"type":20},"2026-03",{"name":383,"class":38},"IHU Strasbourg",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":392,"targetDuration":240,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":4},"100585200","sparobopan-project-spanish-registry-of-robotic-pancreatic-surgery-100585200","NCT06899269","SPAROBOPAN Project (Spanish Registry of Robotic Pancreatic Surgery)","Proyecto SPAROBOPAN (Registro Nacional De Cirugía Róbotica Pancreática)","SPAROBOPAN","Inclusion Criteria:\n\n* robotic pancreatic resections\n* Asa I-III\n* Signed informed consent\n\nExclusion Criteria:\n\n* Less than 18 years old.\n* ASA IV",{"count":393,"type":20},225,"Pancreatic robotic surgery (PRS) has moved from an almost testimonial procedure to a moment of expansion that is not yet clearly defined. In the pioneering centres, the results achieved are superior to those of open surgery. At present, it is not known how many centres perform CRP, what type of operations they perform, what percentage of the total number of pancreatic operations CRP represents and what results are obtained. The aim of our project is to establish a national multicentre registry of robotic pancreatic surgery that will allow us to answer all these questions.\n\nMethodology: This is a one-year prospective multicentre registry involving all general and digestive surgery units in Spain that have a DaVinci robotic platform and wish to participate and perform robotic pancreatectomies.\n\nAll adult patients undergoing robotic pancreatectomy at participating Spanish centres who meet the inclusion criteria will be included. The registry will be open until 31 March 2026 to include post-operative morbidity and mortality at 90 days. The number of pancreatic surgeries performed in that centre during the same period will be counted to determine the percentage of robotic pancreatic surgery per centre. Intraoperative complications will be measured according to the Satava classification modified by Halls et al. Postoperative complications will be classified according to the Clavien-Dindo classification and the CCI (Comprehensive Complication Index). Pancreatic fistula, postoperative bleeding and delayed gastric emptying were classified according to the ISGPS classification and biliary fistula according to the ISGLS classification.",[396,26],"Robotic Surgical Procedures","2025-03-21",{"date":399,"type":31},"2025-03-27",{"date":401,"type":20},"2025-04-01",{"date":403,"type":20},"2029-06-30",{"name":405,"class":38},"Hospital General Universitario de Alicante",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":412,"targetDuration":4,"studyType":51,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":39},"100576810","validation-of-an-ai-assisted-pancreatic-eus-system-for-training-improvement-a-prospective-multi-center-randomized-trial-100576810","NCT06790134","Validation of an AI-Assisted Pancreatic EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial","Inclusion Criteria:\n\n1\\. Age ≥18 years old, \\\u003C80 years old 2.Patients who need endoscopic ultrasonography of pancreas; 3. Agree to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria cannot be selected for this trial:\n\nFirst. The patient's physical condition does not meet the requirements of conventional endoscopic ultrasonography:\n\nPoor physical condition, including hemoglobin ≤8.0g\u002Fdl, severe cardiopulmonary insufficiency, etc. Anesthesia assessment failed Pregnancy or breastfeeding In the acute stage of chemical and corrosive injury, it is very easy to cause perforation Recent acute coronary syndrome or clinically unstable ischemic heart attack Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure\\> 90mmHg), patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome.\n\nSecond. Disagree to participate in this study.\n\nThird. There are other problems that do not meet the requirements of this research or that affect the results of the research:\n\nPancreatic disease has undergone surgery or radiotherapy and chemotherapy beforehand; Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.",{"count":413,"type":20},200,[157],"The goal of this clinical trial is to verify the auxiliary role of the artificial intelligence (AI) system in pancreatic endoscopic ultrasound (EUS) scans. The main questions it aims to answer are as follows:\n\n1. A comparison of the image recognition accuracy between the AI system and EUS endoscopists.\n2. Whether the AI system can improve the quality of scans for EUS endoscopists. Participants will conduct EUS scanning with or without the assistance of the AI system.",[26],"2025-01-17",{"date":419,"type":31},"2025-01-23",{"date":421,"type":20},"2025-01-15",{"date":423,"type":20},"2026-03-30",{"name":425,"class":38},"The Third Xiangya Hospital of Central South University",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":432,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":51,"phases":436,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":450,"locationsCount":39},"100568629","smartglass-guided-ercp-with-cannulation-of-native-papilla-10-100568629","NCT06683716","SmartGlass-Guided ERCP with Cannulation of Native Papilla 1.0","Remote Assistance Via Smart Glasses Compared to In-person Assistance for Cannulation of the Native Papilla During Endoscopic Retrograde Cholangiopancreatography","EmeRald","Inclusion criteria\n\n* Adult patients aged ≥ 18 years without previous papillotomy Exclusion criteria\n* Cannulation of the minor papilla necessary\n* Significant comorbidity\n* Haemodynamic instability\n* Pregnant women\n* Refusal or inability to give written informed consent for the study\n* Instructor had to perform the examination himself\u002Fherself",{"count":435,"type":20},170,[157],"The aim of this prospective randomized study is to evaluate whether telemedical assistance via SmartGlasses is equivalent to physical presence in teaching Endoscopic Retrograde Cholangiopancreaticography (ERCP) in terms of examination success and safety. Endoscopic papilla cannulation is a key skill for successful ERCP and therefore a measurable primary endpoint of the study. This can be measured as the time (in seconds\u002Fminutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct).",[439,26],"Biliary Tract Diseases",[441,442,443],"Telemedicine","Training Technique","Cholangiopancreatography, Endoscopic Retrograde","2024-11-08",{"date":446,"type":31},"2024-11-12",{"date":448,"type":20},"2025-01-02",{"date":330,"type":20},{"name":451,"class":38},"Helios Kliniken Schwerin",{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":182,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":461,"conditions":462,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":39},"100519243","pancreatic-cancer-screening-through-the-detection-of-elastase-1-combined-with-other-examinations-100519243","NCT06041009","Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations","Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations: A Multicenter, Prospective, Diagnostic Clinical Cohort Study.","Inclusion Criteria:\n\nCase groups (matching any of the following):\n\n1. Patients with pancreatic cancer with recognized diagnostic criteria or conclusions.\n2. Patients who are the high-risk group of pancreatic cancer.\n3. Patients with solid pseudo papilloma and neuroendocrine tumors of pancreas with recognized diagnostic criteria or conclusions.\n4. Patients with other diseases with abnormally elevated CA19-9.\n\nControl group:\n\n(1) Patients without pancreatic disease assessed by laboratory tests and imaging examinations have no CA19-9 elevation.\n\nExclusion Criteria:\n\n1. Patients who are younger than 18 years of age.\n2. Patients with suspected pancreatic malignant lesions but has no confirmed imaging or pathological diagnosis.\n3. Patients who have not signed informed consent.",{"count":460,"type":20},2100,"This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.",[216,26,463,464,187,86],"Pancreatic Elastase 1","Pancreatic Neuroendocrine Tumor","2024-10-16",{"date":467,"type":31},"2024-10-18",{"date":469,"type":31},"2023-05-05",{"date":471,"type":20},"2025-09-30",{"name":473,"class":38},"Qilu Hospital of Shandong University",{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":482,"enrollmentInfo":483,"targetDuration":485,"studyType":22,"phases":4,"briefSummary":486,"conditions":487,"keywords":495,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":519},"100400392","osprey-is-a-post-market-global-multicentre-observational-prospective-registry-100400392","NCT04493632","OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.","OncoSil Pancreatic Cancer Post-marketing Clinical REgistrY (OSPREY)","OSPREY","Inclusion Criteria:\n\n1. Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC).\n2. Patients who undergo OncoSil™ implantation at an eligible treatment facility.\n3. Patients who have completed and signed the Patient Informed Consent Form (PICF) for the OSPREY Patient Registry.\n4. Pancreatic target tumour recommended size of \\\u003C7 cm (longest diameter) and \\\u003C110 cc volume.\n5. A clinically acceptable ECOG performance status.\n6. Patients ≥ 18 years of age at screening.\n7. To commence gemcitabine-based chemotherapy, (per Standard-of-Care are according to the approved prescribing schedule) post Registry enrolment.\n8. Adequate biochemical tests, coagulation profile, haematological, renal, and hepatic function as determined by the Treating Physician.\n\nExclusion Criteria:\n\n1. Patient Informed Consent Form (PICF) has not been completed and signed for the OSPREY Patient Registry.\n2. Patients treated with OncoSil™ within an approved interventional clinical study (company or investigator-sponsored).\n3. Evidence of distant metastases based on review of baseline CT scan.\n4. More than one primary lesion.\n5. In the opinion of the Treating Physician, EUS-directed implantation posing undue patient risk. This includes:\n\n   * where previous EUS-FNA was considered technically too difficult to perform;\n   * imaging demonstrates multiple collateral vessels surrounding or adjacent to the target tumour within the pancreas;\n   * presence (or significant risk) of varices near to the target tumour.\n6. Evidence of radiographic invasion into stomach or duodenum (if not certain, confirmation must be obtained prior to enrolment).\n7. In the setting of recent, clinically significant pancreatitis, implantation is not recommended.\n8. Pregnant or intending to commence a pregnancy within 12-months of the intended date of implantation or breastfeeding.\n9. Patients who have a known history of hypersensitivity to silicon or phosphorous, or any of the OncoSil™ components","90 Years",{"count":484,"type":20},500,"24 Months","The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry.\n\nThe Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSil™. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSil™ device.",[488,489,490,491,492,493,26,494],"Pancreatic Neoplasm","Digestive System Neoplasm","Neoplasms by Site","Neoplasms","Endocrine Gland Neoplasm","Digestive System Disease","Endocrine System Diseases",[160,496,497,498,499,500,501,502,503,504,505,506,507,508,509],"Pancreas","Metastases","Pancreatic tumor","Unresectable","Locally advanced","Implantable","Radiographic","Device","Phosphorous-32","OncoSil™","Brachytherapy","Gemcitabine","Nab-paclitaxel","Abraxane","2024-04-29",{"date":512,"type":31},"2024-04-30",{"date":514,"type":31},"2022-04-12",{"date":516,"type":20},"2027-10-01",{"name":518,"class":70},"OncoSil Medical Limited",9,{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":529,"conditions":530,"keywords":531,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":541,"leadSponsor":543,"locationsCount":39},"100502603","pancreatic-disease-cohort-of-toulouse-100502603","NCT05824403","PAncreatic Disease Cohort of TOuLouse","PACTOL","Inclusion Criteria:\n\n* Patients with inflammatory or cystic exocrine pancreatic pathology\n* Patient able to read and understand the information leaflet\n* Patients who have agreed to participate in the study and have signed the free and informed consent\n* Patients affiliated to a social security system (including AME)\n\nExclusion Criteria:\n\n* Patient with pancreatic cancer pathology\n* Patients with active cancer, whatever the origin\n* Pregnant or breastfeeding patients\n* Patients under legal protection, guardianship or trusteeship",{"count":528,"type":20},300,"This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.",[26],[532,533,534,535,536],"Pancreatic cyst","Acute pancreatitis","chronic pancreatitis","Intra Pancreatic Mucinous Neoplasia","diagnosis","2023-11-28",{"date":539,"type":31},"2023-12-04",{"date":537,"type":31},{"date":542,"type":20},"2027-12",{"name":544,"class":38},"University Hospital, Toulouse",{"id":546,"slug":547,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":182,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":554,"conditions":555,"keywords":559,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":39},"100520318","improving-pancreatic-cancer-care-by-the-use-of-computational-science-and-technology-100520318","NCT06055010","Improving Pancreatic Cancer Care by the Use of Computational Science and Technology","IMPACT","Inclusion Criteria:\n\n* ≥18 years of age\n* Patients who received diagnostic procedures and\u002For treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database and healthy individuals who received an abdominal CT-scan (controls)\n\nExclusion Criteria:\n\n\\- Subjects who object to the use of their data for the purpose of scientific research",{"count":553,"type":20},5000,"The goal of the IMPACT project is to set up a data sharing infrastructure between expert centers for pancreatic surgery that enables training, testing and validation of computer science tools to improve quality of care for patients with pancreatic cancer.",[160,188,556,26,557,558],"Pancreatic Adenocarcinoma","Pancreas Adenocarcinoma","Pancreas Cyst",[560,561,562,160],"Artificial Intelligence","Data Science","Computer Science","2023-09-22",{"date":565,"type":31},"2023-09-26",{"date":567,"type":31},"2014-01-01",{"date":569,"type":20},"2029-12-31",{"name":571,"class":38},"UMC Utrecht",{"id":573,"slug":574,"hasResults":11,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":580,"targetDuration":582,"studyType":22,"phases":4,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":39},"100347740","registry-of-pancreatic-disease-100347740","NCT03807687","Registry of Pancreatic Disease","Registry of Subjects Affected by Pancreatic Disease and Evaluated at the Pancreas Institute of Verona","PAD-R","Inclusion Criteria:\n\n* any type of pancreatic disease: inflammatory and neoplastic (including solid and cystic lesions)\n\nExclusion Criteria:\n\n* physically or mentally inability to provide consent",{"count":581,"type":20},3000,"27 Years","This clinical data registry records information about the health status and healthcare performances received by participants affected by every type of pancreatic disease or disorder. All data (demographic, clinical, biochemical, radiological, pharmacological, genetic...) and audio and\u002For video recording from operative room are collected in order to be used for prospective or retrospective studies.",[26,86,187],"2019-01-15",{"date":587,"type":31},"2019-01-17",{"date":589,"type":31},"2016-12-01",{"date":591,"type":20},"2046-12-01",{"name":593,"class":38},"Azienda Ospedaliera Universitaria Integrata Verona"]